Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jandeleit

Showing results (1-10 of 190) with videos related to

Pageof 19
Sort By:
Nature Clinical Practice. Nephrology|October 27, 2006
Does the risk of developing diabetes in hypertensive kidney disease vary with different antihypertensive agents?Karin Jandeleit-Dahm
Cardiovascular Research|January 20, 2021
Endothelin in diabetes-associated atherosclerosis: opportunity 'NOX'Karin Jandeleit-Dahm
Journal of Human Hypertension|March 18, 2006
Dual ACE/NEP inhibitors - more than playing the ACE cardK A M Jandeleit-Dahm
Angewandte Chemie (International Ed. in English)|October 3, 1999
Combinatorial Materials Science and CatalysisJandeleit, Schaefer, Powers, et al.
Diabetes|June 20, 2023
Cytochrome-Derived EETs, VEGF-A, and NOX4: Piecing the Puzzle TogetherKarin Jandeleit-Dahm, Jaroslawna Meister
Endocrinology and Metabolism Clinics of North America|September 9, 2006
Hypertension and diabetes: role of the renin-angiotensin systemKarin Jandeleit-Dahm, Mark E Cooper
Journal of Molecular Medicine (Berlin, Germany)|April 2, 2014
The pathobiology of diabetic vascular complications--cardiovascular and kidney diseaseStephen P Gray, Karin Jandeleit-Dahm
Current Opinion in Nephrology and Hypertension|February 22, 2002
Hypertension and diabetesKarin Jandeleit-Dahm, Mark E Cooper
Current Pharmaceutical Design|May 14, 2008
The role of AGEs in cardiovascular diseaseKarin Jandeleit-Dahm, Mark E Cooper
Diabetes & Vascular Disease Research|April 26, 2019
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?Nordin Mj Hanssen, Karin Am Jandeleit-Dahm
Pageof 19

Showing results (1-10 of 190) with videos related to

Sort By:
Pageof 19
Nature Clinical Practice. Nephrology|October 27, 2006
Does the risk of developing diabetes in hypertensive kidney disease vary with different antihypertensive agents?Karin Jandeleit-Dahm
Cardiovascular Research|January 20, 2021
Endothelin in diabetes-associated atherosclerosis: opportunity 'NOX'Karin Jandeleit-Dahm
Journal of Human Hypertension|March 18, 2006
Dual ACE/NEP inhibitors - more than playing the ACE cardK A M Jandeleit-Dahm
Angewandte Chemie (International Ed. in English)|October 3, 1999
Combinatorial Materials Science and CatalysisJandeleit, Schaefer, Powers, et al.
Diabetes|June 20, 2023
Cytochrome-Derived EETs, VEGF-A, and NOX4: Piecing the Puzzle TogetherKarin Jandeleit-Dahm, Jaroslawna Meister
Endocrinology and Metabolism Clinics of North America|September 9, 2006
Hypertension and diabetes: role of the renin-angiotensin systemKarin Jandeleit-Dahm, Mark E Cooper
Journal of Molecular Medicine (Berlin, Germany)|April 2, 2014
The pathobiology of diabetic vascular complications--cardiovascular and kidney diseaseStephen P Gray, Karin Jandeleit-Dahm
Current Opinion in Nephrology and Hypertension|February 22, 2002
Hypertension and diabetesKarin Jandeleit-Dahm, Mark E Cooper
Current Pharmaceutical Design|May 14, 2008
The role of AGEs in cardiovascular diseaseKarin Jandeleit-Dahm, Mark E Cooper
Diabetes & Vascular Disease Research|April 26, 2019
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?Nordin Mj Hanssen, Karin Am Jandeleit-Dahm
Pageof 19